Together, our data indicate the feasibility of achieving synergistic antileukemic effects with asparaginase and dexamethasone without an undesired increase in osteonecrosis using simple changes to the schedule of combination chemotherapy. This evidence concerns the gene ASPG and osteonecrosis.